Sign in

You're signed outSign in or to get full access.

Miles Minter

Partner and Equity Research Analyst at William Blair Investment Management, LLC

Myles Minter, Ph.D., is a Partner and Equity Research Analyst at William Blair, specializing in biotechnology equity research with a focus on central nervous system and neurobiology-driven drug development. He covers companies including Contineum Therapeutics, Axsome Therapeutics, Minerva Neurosciences, and has provided expert commentary on major industry acquisitions involving firms like Neurocrine Biosciences. Since joining William Blair in October 2017, following a postdoctoral appointment at the University of Chicago, Minter has initiated coverage on pivotal biotech companies and contributed to expanding the firm's sector expertise. He holds a Ph.D. in neuropharmacology and a Bachelor of Biomedical Science from the University of Melbourne, and is a registered securities professional, though specific FINRA registration numbers are not publicly listed.

Miles Minter's questions to NEUROCRINE BIOSCIENCES (NBIX) leadership

Question · Q4 2025

Miles Minter inquired about the CRENESSITY sales force expansion onboarding in April, asking if it's essential for maintaining steady new patient flow or if it's expected to significantly inflect product growth in the second half of the year.

Answer

Chief Commercial Officer Eric Benevich explained that the expansion is an investment in growth, allowing the team to go deeper within the existing prescriber base and expand reach into additional potential prescribers like PCPs and OB/GYNs. He noted the expansion is completed, training is underway, and the new team will deploy in Q2, creating additional bandwidth. CFO Matt Abernethy added a note about a 5% gross-to-net impact in Q1 2026 for CRENESSITY due to commercial copay reset.

Ask follow-up questions

Fintool

Fintool can predict NEUROCRINE BIOSCIENCES logo NBIX's earnings beat/miss a week before the call

Question · Q4 2025

Miles Minter asked about the CRENESSITY sales force expansion onboarding in April, questioning if it is necessary to maintain steady new patient flow or if it is expected to inflect product growth in the second half of the year.

Answer

Eric Benevich, Chief Commercial Officer, characterized the expansion as an investment in growth, noting that the initial sales force size was determined pre-launch. He explained that the expansion, though not a large number of FTEs, will allow deeper engagement with existing prescribers (two-thirds have treated only one patient) and expand reach into non-endocrinology specialties like primary care and OB/GYNs. Matt Abernethy, Chief Financial Officer, also noted a ~5% gross-to-net impact for CRENESSITY in Q1 due to commercial copay resets.

Ask follow-up questions

Fintool

Fintool can write a report on NEUROCRINE BIOSCIENCES logo NBIX's next earnings in your company's style and formatting

Miles Minter's questions to BIOGEN (BIIB) leadership

Question · Q2 2025

Jake, on for Miles Minter at William Blair, asked about the selzartamab opportunity in antibody-mediated rejection (AMR), how Biogen models the market, and the influence of competitor data on expansion strategies.

Answer

CEO Christopher Viehbacher estimated the addressable AMR market at approximately $1.5 billion annually and expressed confidence that selzartamab is positioned to be first-to-market. Priya Singhal, EVP & Head of Development, added that they are expanding into a fourth indication, late MBI, a newly classified rejection phenotype which represents an additional 5,000-6,000 patients and augments the overall opportunity.

Ask follow-up questions

Fintool

Fintool can predict BIOGEN logo BIIB's earnings beat/miss a week before the call